Thurston Springer Miller Herd & Titak Inc. Makes New $65,000 Investment in Novo Nordisk A/S (NYSE:NVO)

Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 453 shares of the company’s stock, valued at approximately $65,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. GQG Partners LLC grew its holdings in shares of Novo Nordisk A/S by 654.6% during the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after buying an additional 3,151,584 shares during the last quarter. Capital International Investors boosted its stake in Novo Nordisk A/S by 22.3% during the 4th quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock valued at $736,121,000 after purchasing an additional 1,297,536 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Novo Nordisk A/S by 1,300.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock worth $159,703,000 after purchasing an additional 1,155,313 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Novo Nordisk A/S by 10.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after purchasing an additional 823,036 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in shares of Novo Nordisk A/S by 10,359.2% during the fourth quarter. International Assets Investment Management LLC now owns 819,688 shares of the company’s stock valued at $84,797,000 after purchasing an additional 811,851 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO traded down $7.25 on Wednesday, reaching $122.87. The company’s stock had a trading volume of 3,595,298 shares, compared to its average volume of 4,428,563. Novo Nordisk A/S has a 12-month low of $86.96 and a 12-month high of $148.15. The stock has a market capitalization of $551.38 billion, a P/E ratio of 44.87, a PEG ratio of 1.33 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock’s 50 day simple moving average is $137.93 and its two-hundred day simple moving average is $129.65.

Analysts Set New Price Targets

Several research firms recently commented on NVO. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. Argus lifted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday. Finally, BMO Capital Markets restated an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.